Several longevity companies announced executive appointments this week – here’s a selection of the top stories.
Amazentis/Timeline
Longevity health science company Amazentis has rebranded as Timeline and appointed Brian Ray as its new CEO. Ray was most recently the CEO of Garden of Life, the billion-dollar supplements company he co-founded in 2000 and later sold to Nestlé Health Science.
“We are thrilled that Brian is joining as CEO to help us translate over a decade of research and build the first billion-dollar longevity consumer health brand backed by science of the highest rigor,” said Patrick Aebischer, Chairman and co-founder of Timeline. “He brings with him extensive experience and a proven track record of growing iconic leading nutrition brands.”
Ray will lead Timeline’s US operations as the company plans to become the world’s leading longevity consumer health brand. Chris Rinsch, co-founder of Amazentis and its founding CEO, will take on the role of President and assumes responsibility for international markets, global innovation and skin health.
“Timeline is one of the most scientifically studied nutrition and skin care brands I have ever seen,” said Ray. “Having significant human clinical studies dedicated to the anti-aging and longevity space makes them very special and unique. I’m excited to join the team.”
Organicell Regenarative Medicine
Regenerative therapeutics developer Organicell appointed Dr Harry L Leider, as its new CEO. Leider is an experienced healthcare executive and entrepreneur, responsible for advancing breakthroughs in patient care across multiple sectors of the healthcare industry. Prior to joining Organicell, he served as the Chief Medical Officer and Executive Vice President of Gelesis, a biotech company specializing in therapies for obesity.
“Harry brings an extensive track record of successfully launching innovative therapeutics and services that have positively impacted the practice of medicine, and I am honored and excited to welcome him to our seasoned leadership team,” said Ian Bothwell, CFO of Organicell. “Harry’s research, and commercial expertise, along with his broad strategic business perspective, will enable Organicell to rapidly advance its successful research and commercial programs while transforming the regenerative medicine space.”
BrainStorm Cell Therapeutics
Targeting neurodegenerative disease, BrainStorm has appointed Nir Naor as a board member, chairman of its Audit Committee, and member of its Governance, Nomination, and Compensation Committee. BrainStorm aims to advance innovative stem cell therapies for debilitating neurodegenerative diseases, holding the rights to the NurOwn technology platform used in the production of autologous MSC-NTF cells.
Naor, a highly experienced CFO and finance leader with over 20 years of global work experience, brings valuable expertise in finance and compliance to BrainStorm. His appointment signifies the company’s commitment to enhancing its finance capabilities and preparing for potential commercial success.
“I am delighted to join BrainStorm at this exciting point in the company’s evolution,” said Naor. “I am impressed by the vision of the management team and in their commitment to serving ALS patients, who are in dire need of new treatments.”
HAYA Therapeutics
Precision medicine company HAYA has appointed Dr Douglas L. Mann as the Chairperson of its Clinical Advisory Board. Mann, a renowned cardiologist and researcher, will contribute his expertise as the company advances its lead heart failure candidate, HTX-001, towards clinical development.
HAYA Therapeutics focuses on developing RNA-guided programmable precision medicines that target long non-coding RNAs. The company’s innovative platform has the potential to modify pathological cell states, starting with cardiac fibrosis linked to heart failure.
“Through their platform, HAYA developed HTX-001, a targeted fibrosis-modifying therapy for heart failure,” said Mann. “Since patients with non-obstructive hypertrophic cardiomyopathy (HCM), a rare disease, have limited treatment options, it is essential to bring new therapeutic interventions into clinical testing. Beyond non-obstructive HCM, the unique properties of HTX-001 potentially allow the candidate to be used for the treatment in other cardiac indications.”
